Fred Hutchinson Cancer Research Center Collaborates with Alkermes plc to Conduct Clinical Trial for Novel Immuno-Oncology Drug Candidate

Fred Hutchinson Cancer Research Center Collaborates with Alkermes plc to Conduct Clinical Trial for Novel Immuno-Oncology Drug Candidate

Fred Hutchinson Cancer Research Center (Fred Hutch) and Alkermes plc (ALKS) inked a collaborative deal where the parties will conduct a Phase II multi-site trial for ALKS 4230, a novel engineered fusion protein designed to selectively expand tumor-killing immune cells...

Pin It on Pinterest